Fig. 4.

Therapeutic strategies to promote remyelination. The left panel shows therapeutic strategies to activate OPC differentiation. MD1003 increases fatty acid synthesis trough acetyl CoA carboxylase activation. Miconazole drives ERK phosphorylation. 9-Cis retinoic acid and Sobetirome act on nuclear receptor Retinoic X receptor gamma and Thyroid hormone receptor, respectively. The right panel illustrates alternative strategies blocking inhibitory signals. Clemastine drives remyelination by antagonising muscarinic receptor activation. Monoclonal antibodies directed against Nogo-A or the receptor LINGO-1 cancel the inhibitory signalling. A polyclonal antibody directed against ephrinB3 prevents its association with EphA4. MTP-PlexA1 promotes both OPC differentiation and migration by blocking Sema3A-induced NRP1/Plexin-A1 dimerization